Long-acting injectable hormonal dosage forms for contraception

Pharmaceutical Research

Volumn 32, Issue 7, 2015, Pages 2180-2191

  Wu, Linfeng ^a   Janagam, Dileep R ^a   Mandrell, Timothy D ^a   Johnson, James R ^a   Lowe, Tao L ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

contraception; in situ forming depot systems; microcrystals; microspheres; steroidal progestogens

Indexed keywords

LONG ACTING DRUG; MEDROXYPROGESTERONE ACETATE; MICROSPHERE; CONTRACEPTIVE AGENT; DELAYED RELEASE FORMULATION; DRUG CARRIER; PROGESTERONE DERIVATIVE;

CLINICAL TRIAL (TOPIC); CRYSTAL; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SCREENING; FEMALE; HORMONAL CONTRACEPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUSPENSION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CONTRACEPTION; DELAYED RELEASE FORMULATION; DRUG RELEASE; INTRAMUSCULAR DRUG ADMINISTRATION; PARTICLE SIZE; PHARMACEUTICS; PRECLINICAL STUDY; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; DRUG LIBERATION; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MICROSPHERES; MOLECULAR STRUCTURE; PARTICLE SIZE; PROGESTERONE CONGENERS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84930182207     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1686-2     Document Type: Review

References (111)

1. Newton J. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update. 1995;1(3):231-63.
2. Garza-Flores J, Hall PE, Perez-Palacios G. Long-acting hormonal contraceptives for women. J Steroid Biochem Mol Biol. 1991;40(4-6):697-704.
3. Singh M, Saxena BB, Singh R, Kaplan J, Ledger WJ. Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable polydl-lactide-co-glycolide microspheres (NET-90): phase III clinical study. Adv Contracept. 1997;13:1-11.
4. Kulier R, Helmerhorst FM, Maitra N, Gülmezoglu AM. Effectiveness and acceptability of progestogens in combined oral contraceptives-a systematic review. Reprod Health. 2004;1:1.
5. Kulier R et al. Effectiveness and acceptability of progestogens in combined oral contraceptives-a systematic review. Reprod Health. 2004;1(1):1.
6. Rosendaal F, Helmerhorst F, Vandenbroucke J. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22(2):201-10.
7. Sitruk-Ware R, Nath A, Mishell DR, Jr. Contraception technology: past, present and future. Contraception. 2012.
8. Sitruk-Ware R. Reprint of pharmacological profile of progestins. Maturitas. 2008;61(1):151-7.
9. Zhang Y, Li C-X, Ning M-Y, Duan X-Y, Liu Y. Preparation and evaluation of intravaginal ring containing drospirenone. Adv Pharm Sci. 2013;2013:11.
10. Zhang Y et al. Preparation and evaluation of intravaginal ring containing drospirenone. Adv Pharm Sci. 2013;2013:11.
11. Rajesh N, Rowan S. Female contraception: present and future perspectives. Curr Womens Health Rev. 2009;5(3):167-75.
12. Potts DM, Siemens AJ. Where next with long-acting steroids? IPPF Med Bull. 1984;18(3):2-3.
13. Delvadia D. Reversible long-acting contraceptives. J Am Osteopath Assoc. 1997;97(8 SUPPL. 1):S8-S12.
14. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179(3):577-82.
15. Ruminjo JK, Sekadde-Kigondu CB, Karanja JG, Rivera R, Nasution M, Nutley T. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Contraception. 2005;72:138-45.
16. Ruminjo JK et al. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Contraception. 2005;72(2):138-45.
17. Chue P. Risperidone long-acting injection. Expert Rev Neurother. 2003;3(4):435-46.
18. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm. 2004;58:445-55.
19. Beck LR, Pope VZ, Tice TR, Gilley RM. Long-acting injectable microsphere formulation for the parenteral administration of levonorgestrel. Adv Contracept. 1985;1:119-29.
20. Wang SH, Zhang LC, Lin F, Sa XY, Zuo JB, Shao QX, et al. Controlled release of levonorgestrel from biodegradable poly(D, L-lactide-co-glycolide) microspheres: in vitro and in vivo studies. Int J Pharm. 2005;301:217-25.
21. Dhanaraju MD, RajKannan R, Selvaraj D, Jayakumar R, Vamsadhara C. Biodegradation and biocompatibility of contraceptive-steroid-loaded poly (dl-lactide-co-glycolide) injectable microspheres: in vitro and in vivo study. Contraception. 2006;74:148-56.
22. Sun Y, Wang J, Zhang X, Zhang Z, Zheng Y, Chen D, et al. Synchronic release of two hormonal contraceptives for about one month from the PLGA microspheres: in vitro and in vivo studies. J Control Release. 2008;129:192-9.
23. Machado SR, Lunardi LO, Tristao AP, Marchetti JM. Preparation and characterization of D, L-PLA loaded 17-beta-Estradiol valerate by emulsion/evaporation methods. J Microencapsul. 2009;26:202-13.
24. Machado SR et al. Preparation and characterization of D, L-PLA loaded 17-beta-Estradiol valerate by emulsion/evaporation methods. J Microencapsul. 2009;26(3):202-13.
25. Trantolo D, Hsu Y-Y, Gresser J, Wise D, Moo-Young A. Biodegradable systems for long-acting nesterone. In: Wise D, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker, Inc.; 2000.
26. Trantolo D et al. Biodegradable systems for long-acting nesterone. In: Wise D, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker, Inc; 2000.
27. Rivera R, Alvarado G, Aldaba CFS, Hernandez A. Norethisterone contraceptive microspheres. J Steroid Biochemistry. 1987;27:1003-7.
28. Grubb GS, Welch JD, Cole L, Goldsmith A, Rivera R. A comparative evaluation of the safety and contraceptive effectiveness of 65 mg and 100 mg of 90-day norethindrone (NET) injectable microspheres: a multicenter study. Fertil Steril. 1989;51:803-10.
29. Grubb GS et al. A comparative evaluation of the safety and contraceptive effectiveness of 65 mg and 100 mg of 90-day norethindrone (NET) injectable microspheres: a multicenter study. Fertil Steril. 1989;51(5):803-10.
30. Kempe S, Mäder K. In situ forming implants - an attractive formulation principle for parenteral depot formulations. J Control Release. 2012;161(2):668-79.
31. Junkmann K. Long-acting steroids in reproduction. Recent Prog Horm Res. 1957;13:389-419.
32. Shearman RP. The development of depot contraceptives. J Steroid Biochemistry. 1975;6(6):899-902.
33. Depo-Provera® Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=522.
34. Depo-subQ Provera 104® Available from: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=11569.
35. Peralta O. Injectable hormonal contraceptives: an overview. Gynaecol Forum. 2000;5(1):p. http://www.medforum.nl/gynfo/leading-article1.asp.
36. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIHCD), A Phase I Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile of a Single Injection of Levonorgestel Butanoate for Female Contraception. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), 2014 May 12 [cited 2014 Sep 7]. (Available from: http://clinicaltrials.gov/show/NCT02173808 NLM Identifier: NCT02173808.).
37. Conrad. http://www.conrad.org/contraception-grid.html. 2012.
38. Conrad. 2012. http://www.conrad.org/contraception-grid.html.
39. Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev. 1997;28(1):43-70.
40. Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol. 1998;16:153.
41. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm. 2004;282:1-18.
42. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm. 2004;282(1-2):1-18.
43. Clarck SL, Crowley AJ, Schmidt PG, Donoghue AR, Piché CA. Long-term delivery of ivermectin by use of poly(D, L-lactic-co-glycolic)acid microparticles in dogs. Am J Vet Res. 2004;65:752-7.
44. Berkland C, Kim K, Pack DW. PLG microsphere size controls drug release rate through several competing factors. Pharm Res. 2003;20:1055-62.
45. Berkland C, Kim K, Pack DW. PLG microsphere size controls drug release rate through several competing factors. Pharm Res. 2003;20(7):1055-62.
46. Berkland C, King M, Cox A, Kim K, Pack DW. Precise control of PLG microsphere size provides enhanced control of drug release rate. J Control Release. 2002;82:137-47.
47. Berkland C et al. Precise control of PLG microsphere size provides enhanced control of drug release rate. J Control Release. 2002;82(1):137-47.
48. Buntner B, Nowak M, Kasperczyk J, Ryba M, Grieb P, Walski M, et al. The application of microspheres from the copolymers of lactide and ε-caprolactone to the controlled release of steroids. J Control Release. 1998;56:159-67.
49. Buntner B et al. The application of microspheres from the copolymers of lactide and ε-caprolactone to the controlled release of steroids. J Control Release. 1998;56(1-3):159-67.
50. Tice TR, Gilley RM. Preparation of injectable controlled-release microcapsules by a solvent-evaporation process. J Control Release. 1985;2:343-52.
51. Dhanaraju MD, Jayakumar R, Vamsadhara C. Influence of manufacturing parameters on development of contraceptive steroid loaded injectable microspheres. Chem Pharm Bull. 2004;52:976-9.
52. Song CX, Sun HF, Feng XD. Microspheres of biodegradable block copolymer for long-acting controlled delivery of contraceptives. Polym J. 1987;19:485-91.
53. Gu ZW, Ye WP, Yang JY, Li YX, Chen XL, Zhong GW, et al. Biodegradable block copolymer matrices for long-acting contraceptives with constant release. J Control Release. 1992;22:3-14.
54. Gu ZW et al. Biodegradable block copolymer matrices for long-acting contraceptives with constant release. J Control Release. 1992;22(1):3-14.
55. Dhanaraju MD, Gopinath D, Ahmed MR, Jayakumar R, Vamsadhara C. Characterization of polymeric poly(ε-caprolactone) injectable implant delivery system for the controlled delivery of contraceptive steroids. J Biomed Mater Res A. 2006;76:63-72.
56. Dhanaraju MD et al. Characterization of polymeric poly(ε-caprolactone) injectable implant delivery system for the controlled delivery of contraceptive steroids. J Biomed Mater Res A. 2006;76(1):63-72.
57. Latha MS, Lal AV, Kumary TV, Sreekumar R, Jayakrishnan A. Progesterone release from glutaraldehyde cross-linked casein microspheres: in vitro studies and in vivo response in rabbits. Contraception. 2000;61:329-34.
58. Latha MS et al. Progesterone release from glutaraldehyde cross-linked casein microspheres: in vitro studies and in vivo response in rabbits. Contraception. 2000;61(5):329-34.
59. Puthli S, Vavia P. Gamma irradiated micro system for long-term parenteral contraception: an alternative to synthetic polymers. Eur J Pharm Sci. 2008;35(4):307-17.
60. Jameela SR et al. Progesterone-loaded chitosan microspheres: a long acting biodegradable controlled delivery system. J Control Release. 1998;52(1-2):17-24.
61. Lu B, Guo RL, Liu C. Studies on an injection of microencapsulated levonorgestrel. In: Whateley TL, editor. Microencapsulation of drugs. UK: Harwood Academic Publishers; 1992. p. 103-21.
62. Lu B, Wang Z, Yang H. Long-acting delivery microspheres of levo-norgestrolpoly (3-hydroxybutyrate): their preparation, characterization and contraceptive tests on mice. J Microencapsul. 2001;18:55-64.
63. Zhong-wei G, Wei-ping Y, Ji-yuan Y, You-xin L, Xian-li C, Ge-wen Z, et al. Biodegradable block copolymer matrices for long-acting contraceptives with constant release. J Control Release. 1992;22:3-14.
64. Zhong-wei G et al. Biodegradable block copolymer matrices for long-acting contraceptives with constant release. J Control Release. 1992;22(1):3-14.
65. Schindler A, et al. Biodegradable polymers for sustained drug delivery. In Contemporary topics in polymer science. Springer; 1977. p. 251-289.
66. Pitt CG et al. Sustained drug delivery systems. I. The permeability of poly (Ïμ â€caprolactone), poly (DLâ€lactic acid), and their copolymers. J Biomed Mater Res. 1979;13(3):497-507.
67. Li YX, Feng XD. Biodegradable polymeric matrix for longâ€acting and zeroâ€order release drug delivery systems. In: Makromolekulare Chemie. Macromolecular Symposia. 1990. Wiley Online Library.
68. Beck LR, Pope VZ. Long-acting injectable norethisterone contraceptive system: review of clinical studies. Res Front Fertil Regul RFFR / PARFR. 1984;3(2):1-10.
69. Beck LR, Ramos RA, Flowers Jr CE. Clinical evaluation of injectable biodegradable contraceptive system. Am J Obstet Gynecol. 1981;140(7):799-806.
70. Beck LR, Cowsar D. Biodegradable microsphere contraceptive system. Acta Eur Fertil. 1980;11(2):139-50.
71. Huang X, Chestang BL, Brazel CS. Minimization of initial burst in poly(vinyl alcohol) hydrogels by surface extraction and surface-preferential crosslinking. Int J Pharm. 2002;248:183-92.
72. Wu L, Brazel CS. Modifying the release of proxyphylline from PVA hydrogels using surface crosslinking. Int J Pharm. 2008;349:144-51.
73. Wu L, Brazel CS. Modifying the release of proxyphylline from PVA hydrogels using surface crosslinking. Int J Pharm. 2008;349(1-2):144-51.
74. Wu J, Kong T, Yeung KWK, Shum HC, Cheung KMC, Wang L, et al. Fabrication and characterization of monodisperse PLGA-alginate core-shell microspheres with monodisperse size and homogeneous shells for controlled drug release. Acta Biomater. 2013;9:7410-9.
75. Cong H, Beck LR. Preparation and pharmacokinetic evaluation of a modified long-acting injectable norethisterone microsphere. Adv Contracept. 1991;7:251-6.
76. Meyer RF, Rogers WB, McClendon MT, Crocker JC. Producing monodisperse drug-loaded polymer microspheres via cross-flow membrane emulsification: the effects of polymers and surfactants. Langmuir. 2010;26:14479-87.
77. Meyer RF et al. Producing monodisperse drug-loaded polymer microspheres via cross-flow membrane emulsification: the effects of polymers and surfactants. Langmuir. 2010;26(18):14479-87.
78. Akamatsu K et al. Preparation of monodisperse chitosan microcapsules with hollow structures using the spg membrane emulsification technique. Langmuir. 2010;26(18):14854-60.
79. Zhao Y et al. Facile preparation of fluorescence-encoded microspheres based on microfluidic system. J Colloid Interface Sci. 2010;352(2):337-42.
80. Sugiura S, Nakajima M, Seki M. Preparation of monodispersed polymeric microspheres over 50 μm employing microchannel emulsification. Ind Eng Chem Res. 2002;41(16):4043-7.
81. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release. 2005;102(2):313-32.
82. Berkland C, Kim K, Pack DW. Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. J Control Release. 2001;73:59-74.
83. Berkland C, Kim K, Pack DW. Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. J Control Release. 2001;73(1):59-74.
84. Cardot JM, Davit BM. In vitro-in vivo correlations: tricks and traps. AAPS J. 2012;14(3):491-9.
85. Pollauf EJ, Kim KK, Pack DW. Small-molecule release from poly(D, L-lactide)/poly(D, L-lactide-co- glycolide) composite microparticles. J Pharm Sci. 2005;94:2013-22.
86. Pollauf EJ, Kim KK, Pack DW. Small-molecule release from poly(D, L-lactide)/poly(D, L-lactide-co- glycolide) composite microparticles. J Pharm Sci. 2005;94(9):2013-22.
87. Dunn RL, Yewey GL, Fujita SM, Josephs KR, Whitman SL, Southard GL, et al. Sustained release of cisplatin in dogs from an injectable implant delivery system. J Bioact Compat Polym. 1996;11:286-300.
88. Eliaz RE, Wallach D, Kost J. Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo. Pharm Res. 2000;17:1546-50.
89. Johansson AK, Linse P, Piculell L, Engström S. Phase behavior of the quaternary poly(DL-lactide-co-glycolide)/monoolein/1-methyl-2-pyrrolidinone/water system: an experimental and theoretical study. J Phys Chem B. 2001;105:12157-64.
90. Johansson AK et al. Phase behavior of the quaternary poly(DL-lactide-co-glycolide)/monoolein/1-methyl-2-pyrrolidinone/water system: an experimental and theoretical study. J Phys Chem B. 2001;105(48):12157-64.
91. Dong S et al. An in situ-forming, solid lipid/PLGA hybrid implant for long-acting antipsychotics. Soft Matter. 2011;7(12):5873-8.
92. Başaran B, Bozkir A. Thermosensitive and pH induced in situ ophthalmic gelling system for ciprofloxacin hydrochloride: hydroxypropyl-β-cyclodextrin complex. Acta Pol Pharm Drug Res. 2012;69:1137-47.
93. Gupta SK, Singhvi IJ. Sustained ophthalmic delivery of moxifloxacin hydrochloride from an pH triggered in situ gelling system. Res J Pharm Technol. 2012;5:1538-42.
94. Royals MA, Fujita SM, Yewey GL, Rodriguez J, Schultheiss PC, Dunn RL. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater Res. 1999;45:231-9.
95. Royals MA et al. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater Res. 1999;45(3):231-9.
96. Astaneh R et al. Effects of ethyl benzoate on performance, morphology, and erosion of PLGA implants formed in situ. Adv Polym Technol. 2008;27(1):17-26.
97. Pandya TP, Modasiya MK, Patel VM. Sustained ophthalmic delivery of ciprofloxacin hydrochloride from an ion-activated in situ gelling system. Der Pharm Lett. 2011;3:404-10.
98. Dunn RL, English JP, Cowsar DR, Vanderbilt DP. Biodegradable in situ forming implants and methods of producing the same. In: USA, editor. USA Patent 4,938,763. USA Patent 4,938,7631990.
99. Dunn RL, English JP, Cowsar DR, Vanderbilt DP. Biodegradable in situ forming implants and methods of producing the same. In: USA Patent 4,938,763, USA, Editor. 1990: USA Patent 4,938,763.
100. Parent M et al. Plga in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release. J Control Release. 2013;172(1):292-304.
101. Thosar SS. Controlled release of a contraceptive steroid from biodegradable and injectable formulations: in vitro and in vivo evaluations. The University of Tennessee Health Science Center, Thesis. 1997.
102. Thosar SS, Shukla AJ, Crowley WR, Johnson JR. Evaluation of the effects of varying formulation factors on the in vitro release of levonorgestrel from a biodegradable injectable drug delivery system. Pharm Res. 1996;13S-298.
103. Gao Z, Shukla AJ, Johnson JR, Crowley WR. Controlled release of a contraceptive steroid from biodegradable and injectable gel formulations: in vitro evaluation. Pharm Res. 1995;12:857-63.
104. Tell L, Shukla A, Munson L, Thosar S, Kass P, Stanton R, et al. A comparison of the effects of slow release, injectable levonorgestrel and depot medroxyprogesterone acetate on egg production in Japanese quail (Coturnix coturnix japonica). J Avian Med Surg. 1999;13:23-31.
105. Tell L et al. A comparison of the effects of slow release, injectable levonorgestrel and depot medroxyprogesterone acetate on egg production in Japanese quail (Coturnix coturnix japonica). J Avian Med Surg. 1999;13(1):23-31.
106. Looper S et al. Efficacy of levonorgestrel when administered as an irradiated, slow-release injectable matrix for feline contraception. Zoo Biol. 2001;20(5):407-21.
107. Wheaton CJ et al. The use of long acting subcutaneous levonorgestrel (LNG) gel depot as an effective contraceptive option for cotton-top tamarins (Saguinus oedipus). Zoo Biol. 2011;30(5):498-522.
108. Yewey GL, Krinick NL, Dunn RL, Radomsky ML, Brouwer G, Tipton AJ. Liquid delivery compositions. In: US Patent 5780044, U. Patent, Editor. USA; 1998.
109. Chen S, Singh J. In vitro release of levonorgestrel from phase sensitive and thermosensitive smart polymer delivery systems. Pharm Dev Technol. 2005;10(2):319-25.
110. Brodbeck KJG-D, Ann T, Shen TT-I. Gel composition and methods. In: US Patent 6130200, U. patent, Editor. USA; 2000.
111. Bowers R. Longer-acting method that is injectable probed. Contracept Technol Updat. 2013;34(3):28-9.